The integration of emerging biomarkers such as PCSK9, EPHX2, AOPPs, and TBARSs offers a promising paradigm shift in our understanding and management of CKD by targeting and tracking underlying disease-driving mechanisms rather than relying solely on eGFR and albuminuria [221]. The gene discussed is EPHX2; the disease is chronic kidney disease.